Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

被引:16
作者
Soares-Weiser, Karla [1 ]
Bechard-Evans, Laura [1 ]
Lawson, Anthony Howard [2 ]
Davis, John [3 ]
Ascher-Svanum, Haya [2 ]
机构
[1] Enhance Reviews Ltd, London, England
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Univ Illinois, Chicago, IL USA
关键词
Antipsychotics; Schizophrenia; Meta-analysis; Systematic review; 2ND-GENERATION ANTIPSYCHOTICS; ATYPICAL ANTIPSYCHOTICS; CONTROLLED-TRIALS; HEALTH-CARE; QUALITY; DRUGS; RISPERIDONE; QUETIAPINE; CLOZAPINE; DISORDER;
D O I
10.1016/j.euroneuro.2012.05.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: This comprehensive review and meta-analysis compared the effectiveness of olanzapine and other antipsychotics in schizophrenia treatment, defining effectiveness as time to all-cause medication discontinuation (primary) and as all-cause treatment discontinuation rates. This study examined randomized clinical trials (RCTs) and observational non-interventional studies. Experimental procedures: Schizophrenia studies that compared olanzapine with individual first- (FGAs) and/or second-generation antipsychotics (SGAs) were included in the meta-analyses. Hazard ratios (HR), risk ratios (RR), and their associated 95% confidence intervals were extracted for RCTs and observational studies. Sensitivity analyses assessed the impact of sources of funding, dose of olanzapine, and allocation concealment method on final results. Results: There were 60 RCTs (N = 33,360) and 27 observational studies (N = 202,591) included. On time to all-cause medication discontinuation, olanzapine was significantly better than aripiprazole, quetiapine, risperidone, ziprasidone and perphenazine for RCTs and better than amisulpride, risperidone, haloperidol, and perphenazine for observational studies. There were no significant differences between olanzapine and clozapine in RCTs or observational studies. All-cause discontinuation rates in RCTs were significantly lower for olanzapine compared to all comparators except amisulpride and clozapine. In observational studies, olanzapine was less effective than clozapine. Industry-sponsored studies favored olanzapine when compared to haloperidol and perphenazine; higher dose of olanzapine favored quetiapine and perphenazine when compared to olanzapine; method of allocation concealment did not generally affect the results. Conclusion: Using a global measure of medication effectiveness (time to all-cause medication discontinuation), olanzapine appears to be more effective - in both RCTs and observational studies - than most SGAs and FGAs, except for clozapine. (c) 2012 Elsevier B.V. and ECNP. All rights reserved.
引用
收藏
页码:118 / 125
页数:8
相关论文
共 50 条
  • [31] All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis
    Dhana, Ashar
    Yen, Hsi
    Yen, Hsuan
    Cho, Eunyoung
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (05) : 1332 - 1343
  • [32] Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis
    De Fruyt, Juergen
    Deschepper, Ellen
    Audenaert, Kurt
    Constant, Eric
    Floris, Michel
    Pitchot, William
    Sienaert, Pascal
    Souery, Daniel
    Claes, Stephan
    JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (05) : 603 - 617
  • [33] Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
    Kishimoto, T.
    Agarwal, V.
    Kishi, T.
    Leucht, S.
    Kane, J. M.
    Correll, C. U.
    MOLECULAR PSYCHIATRY, 2013, 18 (01) : 53 - 66
  • [34] Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis
    Ostacher, Michael
    Ng-Mak, Daisy
    Patel, Pankaj
    Ntais, Dionysios
    Schlueter, Max
    Loebel, Antony
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2018, 19 (08) : 586 - 601
  • [35] Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
    Kishi, Taro
    Matsunaga, Shinji
    Matsuda, Yuki
    Iwata, Nakao
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 2339 - 2351
  • [36] Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study
    Davis, Sonia M.
    Stroup, T. Scott
    Koch, Gary G.
    Davis, Clarence E.
    Rosenheck, Robert A.
    Lieberman, Jeffrey A.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 253 - 265
  • [37] All-cause and specific mortality in patients with gout: A systematic review and meta-analysis
    Wang, Xueyan
    Li, Xuanlin
    Wang, Hongli
    Chen, Min
    Wen, Chengping
    Huang, Lin
    Zhou, Mingqian
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 63
  • [38] Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
    Men, Peng
    Yi, Zhanmiao
    Li, Chaoyun
    Qu, Shuli
    Xiong, Tengbin
    Yu, Xin
    Zhai, Suodi
    BMC PSYCHIATRY, 2018, 18
  • [39] Association of coffee drinking with all-cause mortality: a systematic review and meta-analysis
    Zhao, Yimin
    Wu, Kejian
    Zheng, Jusheng
    Zuo, Ruiting
    Li, Duo
    PUBLIC HEALTH NUTRITION, 2015, 18 (07) : 1282 - 1291
  • [40] Association of Olfactory Impairment With All-Cause Mortality A Systematic Review and Meta-analysis
    Pang, Natalie Yan-Lin
    Song, Harris Jun Jie Muhammad Danial
    Tan, Benjamin Kye Jyn
    Tan, Jun Xiang
    Chen, Ashley Si Ru
    See, Anna
    Xu, Shuhui
    Charn, Tze Choong
    Teo, Neville Wei Yang
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2022, 148 (05) : 436 - 445